Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With A CDK4/6 Inhibitor SHR6390 in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma

NCT03601598 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT03601598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03601598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With A CDK4/6 Inhibitor SHR6390 in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma
Lead sponsor
Harbin Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 30, 2018
Completion date
July 30, 2020
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crc, hcc, nsclc